Merial Limited

Newport Laboratories

Boehringer Ingelheim Animal Health USA Inc.

Randy R Simonson

Russell F Bey

Paulraj Kirubakaran Lawrence

Benjamin Matthew Hause

Simone Oliveira

Kamesh Reddy Sirigireddy

Jonathan D Mahlberg

Mark D Titus

Danielle A McKeown

Tracy A Oleson

Emily A Collin

Kamesh R Sirigireddy

The present invention provides attenuatedstrains that elicit an immune response in animal, compositions comprising said strains, methods of vaccination against, and kits for use with such methods and compositions. The invention further provides novel, genetically-engineered mutations inhyaD and nanPU genes, which are useful in the production of novel attenuatedbacterial strains.

Attenuatedvaccines and methods of making and use thereof

The present invention provides attenuatedstrains that elicit an immune response in animal against, compositions comprising said strains, methods of vaccination against, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to 'shipping fever' or bovine respiratory disease.

[object Object]

Attenuated mannheimia haemolytica vaccines and methods of making and use

The present invention provides attenuatedstrains that elicit an immune response in animals againstcompositions comprising said strains, methods of vaccination against, and kits for use with such methods and compositions. The invention further provides novel, mutagenically-induced mutations ingenes, which are useful in the production of novel attenuatedbacterial strains.

A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the incidence of antibodies against this virus in both pigs and humans. Approximately 10% of pigs and 30% of humans have antibodies to this virus. Additional experimental data show that the virus can infect and transmit in ferrets (a surrogate for human infection studies). In a third aspect, the present invention is the partial genome of this novel influenza C virus. In another aspect, the present invention is a method of detection in animals of this novel influenza C virus.

Influenza C virus and vaccine

The present invention is a live vaccine from a culture of cells ofexhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth. Several SNPs have been identified as associated with specific proteins that are associated with virulence as seen in the literature inor related bacterial species.

The present invention is a culture of cells ofexhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs as a live vaccine. The present invention is also a method of preparing the cell culture, a method of preparing a vaccine from the cell culture, and a live vaccine based on the cell culture. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth.

Growing community of inventors

Worthington, MN, United States of America

Randy R Simonson